Platelet Count Recovery after Endovascular Aneurysm Repair for Abdominal Aortic Aneurysm

Kentaro Inoue, MD, PhD,1,2 Tadashi Furuyama, MD, PhD,1 Shun Kurose, MD,1 Shinichiro Yoshino, MD,1 Ken Nakayama, MD,1 Sho Yamashita, MD,1 Koichi Morisaki, MD, PhD,1 and Masaki Mori, MD, PhD1

Objective: To find a new predictor of endoleak (EL) and aneurysm sac expansion after endovascular aneurysm repair (EVAR), we evaluated the platelet count recovery (PCR) process after EVAR.

Materials and Methods: Two hundred five patients treated with elective EVAR from 2007 to 2015 were retrospectively analyzed. We compared the platelet count ratio until postoperative day (POD) 7 to the presurgical baseline between patients with and without persistent EL (≥ 6 months). Subsequently, we calculated the optimal platelet count ratio for distinguishing persistent EL using receiver-operating characteristics analysis. A platelet count ratio on POD7 ≥118% was defined as the PCR. We evaluated the PCR’s influence on the cumulative aneurysm sac expansion rate.

Results: The average platelet count ratio on POD7 rose above baseline (112%), and the ratio was attenuated by persistent EL (103%). Of 205 patients, 126 (61%) were assigned to the disturbed PCR group (PCR(−) group). Cumulative aneurysm sac expansion rate was higher in the PCR(−) group than the PCR(+) group (34.4% vs. 12.8% in 5 years, p=0.01).

Conclusion: Disturbed PCR after EVAR may be associated with ELs and eventual aneurysm sac expansion.

Keywords: abdominal aortic aneurysm, platelet, endovascular aneurysm repair, endoleak, aneurysm sac expansion

Introduction

Over the past 30 years, endovascular aneurysm repair (EVAR) has been widely used to treat abdominal aortic aneurysms (AAA). The procedure is minimally invasive and has demonstrated perioperative safety, even for high-risk patients. However, follow-up data has identified aneurysm sac expansion after EVAR as a significant complication in 25–40% of the cases.1,2) Furthermore, a recent study suggested that aneurysm sac expansion is an independent risk factor for delayed mortality, requiring re-intervention after EVAR.3) Postoperative aneurysm sac expansion is due primarily to persistent endoleak (EL). Type I or type III EL is regarded as a definitive indication for re-intervention. Further, even some type II ELs can contribute to sac expansion. Still, approximately half of EL cases resolve spontaneously.4–8) Hence, careful follow-up and post-procedural examinations are as important as EVAR operative procedures to long-term patient outcomes.

Contrast-enhanced computed tomography (CT) and color duplex ultrasound imaging are the gold standards for follow-up examinations after EVAR.9,10) These examinations only provide morphological information at that time, which is sometimes insufficient for clinical practice. For instance, detecting type II ELs at a certain point offers very little guidance about the indication for re-intervention because how the type II ELs behave in the future is unclear.9,10) Furthermore, some AAAs can enlarge even in the absence of ELs.11,12) Therefore, post-EVAR surveillance improves with another approach independent of morphological assessment.

Recently, Arnaoutoglou et al. suggested that EVAR causes platelet activation in the first 24 h post-surgery and then platelet count reduction over the next 72 h.13) They also reported a correlation between postoperative platelet activation and total AAA volume, suggesting that platelet count may be predictive of AAA prognosis after EVAR.
However, there are no studies on the association between platelet counts following EVAR and mid- and long-term clinical outcomes. In this study, we monitored the perioperative changes in platelet count and evaluated whether these changes predict the mid-term prognosis of AAAs following EVAR.

Materials and Methods

Study design and ethics approval
This retrospective study assessed patient outcomes using routine diagnostic and treatment data. The hospital institutional ethics committee approved this study, which was conducted under the Declaration of Helsinki (Approval No. 30-466). All patients provided written informed consent before treatment.

Patients
Patients who underwent elective EVAR for non-ruptured AAA from September 2007 to December 2015 were evaluated retrospectively. The group consisted of 303 potential study candidates. We excluded cases with concomitant thoracic aortic aneurysm and/or iliac artery aneurysm to minimize the influence of non-AAA aneurysms on the platelet count. Consequently, we included 230 patients in this retrospective analysis. Patient information included age, sex, smoking history, comorbidities, medications, preoperative platelet count, postoperative platelet count (from postoperative day [POD] 1, POD3 and POD7), aneurysm characteristics (shape, size), treatment procedures, presence/absence of EL, and EL type and outcome (cumulative aneurysm sac expansion rate and overall survival).

Laboratory data and platelet count recovery
All preoperative data, including complete blood count (CBC), were collected within one month before treatment. CBCs were also collected on POD1, POD3, and POD7. In this study, the ratio of postoperative platelet count to the platelet count observed before the operation was defined as the platelet count ratio as follows:

\[
\text{platelet count ratio} = \frac{\text{Platelet count on POD1, 3, 7}}{\text{Preoperative platelet count}} \times 100 \, (\%)
\]

We used available data to calculate the platelet count ratios of patients with and without persistent EL to examine whether the EL could influence platelet count changes.

Next, we conducted a receiver-operating characteristics (ROC) analysis to identify a cut-off value of platelet count ratio on POD7 for high detection of ELs. The cut-off value was calculated with the best accuracy to distinguish persistent EL (≥ 6 months), and the cut-off value was defined as the ‘platelet count recovery (PCR)’ for further analysis.

Aneurysms characteristics and treatment procedures
A CT scan revealed the aneurysm’s shape and size. We assessed the number and model of stent-grafts and the proximal and distal landing details to classify treatment procedures. In this study, we used the Zenith Flex® (Cook Inc., Indianapolis, IN, USA), Powerlink® (Endologix, Irvine, CA, USA), GORE® Excluder® (W. L. Gore & Associates, Flagstaff, AZ, USA), Endurant II® (Medtronic Inc., Santa Rosa, CA, USA) and AORFIX® (Lombard Medical Technologies, Oxfordshire, UK). All EVAR treatments were performed under general anesthesia with surgical cut-down femoral artery access.

Follow-up and diagnosis of endoleak and aneurysm sac expansion
Contrast-enhanced biphasic CT examined patients during the first 7 postoperative days. Follow-up CT scans were also performed 1, 3, 6, and 12 months post-EVAR and then either biannually or annually after that. An EL lasting ≥ 6 months was classified as persistent and assessed as a risk factor for enlarged AAA. Patients were followed-up for mortality and aneurysmal sac growth over time. Aneurysm sac expansion was defined as an increment > 5 mm over the maximum pre-EVAR axial diameter.9,10 The mean follow-up period for all patients was 3.7 ± 0.2 years [95% confidence interval (CI): 3.3–4.0 years].

For further analysis, ELs were classified into two groups as follows. Benign EL included type II ELs with spontaneous resolution or without sac expansion. In contrast, malignant ELs included primary and secondary type I or III ELs and type II ELs with sac expansion during observation.

Midterm outcomes
Cumulative aneurysm sac expansion rate was evaluated as the period to sac growth > 5 mm relative to pre-EVAR regardless of additional treatment. The overall survival rate was also assessed.

Statistical analysis
All statistical analyses were performed using JMP ver.13 (SAS Institute Inc., Cary, NC, USA). Categorical variables are expressed as numbers or percentages and continuous variables as mean with standard error and [range]. The chi-squared test compared the categorical variables. Continuous variables were compared by t-test after confirming the normal distribution using the Shapiro–Wilk test. The ROC analysis calculated the platelet count ratio’s cut-off value on POD7 with the best accuracy to distinguish persistent EL (≥ 6 months). The Kaplan–Meier method estimated the cumulative aneurysm sac expansion and overall survival rates. We compared the resulting Kaplan–Meier curves using the log-rank test. A Cox proportional-
Results

Changes in platelet count ratio after EVAR
We collected baseline platelet count data from all 230 cases (100%), retrieved platelet count data on POD1 and POD3 from 209 cases (91%), and collected data from baseline to POD7 from 205 cases (89%). All patients exhibited a 24% reduced platelet count ratio on POD1, and that reduction remained until POD3 (Fig. 1, dotted line). The average platelet count ratio rose until POD7 (112% ± 2%), with most of the study subjects (140/205, 68%) demonstrating this overshoot (>100%).

The patients were divided into two groups according to the presence or absence of persistent EL (all types) (Fig. 1) and compared platelet count values. The absolute preoperative platelet count did not differ between EL(+) and EL(−) groups (185 ± 9 × 10³/µL [168–206] vs. 188 ± 4 × 10³/µL [180–197]; p = 0.74). Similarly, the magnitude of the transient platelet count dip during POD1 to POD3 did not differ. Alternatively, the magnitude of the overshoot on POD7 was larger in the EL(−) group than the EL(+) group (115% ± 2% vs. 103% ± 5%, p = 0.02).

Endoleak and the platelet count ratio on POD7
Within the first post-EVAR month, CT scans detected primary EL in 57 cases, including 3 cases of type I and 54 cases of type II. Of these type II cases, 15 of 54 (28%) disappeared spontaneously at 6 months or more post-EVAR, whereas 7 developed to type I (13%) and 3 to type III (6%). One case had a de novo secondary type II EL. Consequently, persistent EL (≥6 months) was recognized in 43 of 230 patients (20%) (10 type I cases, 30 type II
cases, and three type III cases).

We compared the platelet count ratio on POD7 according to EL type (Fig. 2). Patients with no or only benign EL (type II with spontaneous resolution or without sac expansion) showed a recovery ratio above the baseline (>113%). Meanwhile, the platelet count of patients with “malignant” ELs (type I or type III or type II with sac expansion) could not recover the decrease (<100%).

We calculated the cut-off value with best accuracy to distinguish persistent EL (≥6 months), and the cut-off platelet count ratio (PCR) in our patients was 118% (area under the curve = 0.62, sensitivity = 79.5%, specificity = 43.4%).

Table 1  Patient characteristics and laboratory findings from AAA patient groups with and without optimal PCR*

| Variables                      | Total (n=205) | PCR(+) (n=79) | PCR(−) (n=126) | P-value |
|--------------------------------|---------------|---------------|----------------|---------|
| Age (years)                    | 75.0±0.5 (73.9–76.0) | 73.8±0.9 (72.0–75.6) | 76.1±0.7 (74.7–77.6) | 0.05    |
| Sex (male)                     | 173 (84)      | 74 (94)       | 99 (79)        | 0.005   |
| Body mass index                | 23.1±0.2 (22.6–23.5) | 23.3±0.4 (22.4–24.2) | 22.8±0.3 (22.1–23.5) | 0.37    |
| Smoking history                |               |               |                |         |
| Current                        | 48 (24)       | 21 (27)       | 27 (22)        | 0.04    |
| Past                           | 56 (27)       | 14 (18)       | 42 (34)        |         |
| Never                          | 100 (49)      | 44 (56)       | 56 (45)        |         |
| Hypertension                   | 169 (82)      | 62 (78)       | 107 (85)       | 0.26    |
| Diabetes mellitus              | 51 (25)       | 18 (23)       | 33 (26)        | 0.62    |
| Dyslipidaemia                  | 74 (36)       | 31 (39)       | 43 (34)        | 0.46    |
| Coronary artery disease        | 65 (32)       | 21 (27)       | 44 (35)        | 0.22    |
| Cerebrovascular disease        | 54 (26)       | 24 (30)       | 30 (24)        | 0.33    |
| Ejection fraction (%)          | 65.4±0.8 (63.8–67.1) | 65.0±1.4 (62.2–67.7) | 65.9±1.1 (63.7–68.0) | 0.60    |
| FEV1.0%                        | 68.6±0.8 (67.0–70.2) | 67.5±1.4 (64.7–70.2) | 69.8±1.1 (67.6–71.9) | 0.19    |
| Atrial fibrillation            | 18 (9)        | 5 (6)         | 13 (10)        | 0.45    |
| End-stage renal disease        | 6 (3)         | 2 (3)         | 4 (3)          | 1.00    |
| Medication                     |               |               |                |         |
| Statin                         | 105 (51)      | 45 (57)       | 60 (48)        | 0.20    |
| Antiplatelet therapy           |               |               |                |         |
| None                           | 99 (48)       | 36 (46)       | 63 (50)        | 0.57    |
| SAPT                           | 84 (41)       | 36 (46)       | 48 (38)        |         |
| DAPT                           | 22 (11)       | 7 (9)         | 15 (12)        |         |
| Anticoagulant therapy          | 18 (9)        | 8 (10)        | 10 (8)         | 0.62    |
| Laboratory data                |               |               |                |         |
| White blood cells (10³/µL)     | 6.6±0.1 (6.3–6.8) | 6.6±0.2 (6.1–7.0) | 6.5±0.2 (6.1–6.9) | 0.79    |
| Haemoglobin (g/dL)             | 12.8±0.1 (12.5–13.0) | 12.8±0.2 (12.4–13.2) | 12.7±0.2 (12.4–13.0) | 0.55    |
| Platelet count (10³/µL)        | 188±4 (180–195) | 173±6 (160–186) | 194±5 (183–204) | 0.01    |
| C-reactive protein (mg/dL)     | 0.75±0.01 (0.51–0.99) | 0.73±0.02 (0.33–1.13) | 0.70±0.16 (0.38–1.00) | 0.88    |
| Albumin (g/dL)                 | 4.02±0.03 (3.96–4.09) | 4.02±0.05 (3.91–4.13) | 4.02±0.04 (3.94–4.11) | 0.98    |
| Creatinine (mg/dL)             | 1.14±0.06 (1.03–1.26) | 1.20±0.1 (1.00–1.41) | 1.15±0.08 (0.99–1.31) | 0.63    |
| PT-INR                         | 1.07±0.01 (1.05–1.09) | 1.09±0.02 (1.04–1.13) | 1.07±0.02 (1.04–1.10) | 0.54    |
| APTT-T (s)                     | 33.1±0.4 (32.4–33.8) | 33.4±0.6 (32.2–34.6) | 33.3±0.5 (32.3–34.2) | 0.88    |

*Optimal PCR was defined as ≥118% by ROC analysis. Continuous data are shown as mean±standard error and categorical data as numbers (%).

FEV1.0%: forced expiratory volume % in 1s; SAPT: single antiplatelet therapy; DAPT: dual antiplatelet therapy; PT-INR: prothrombin time-international normalized ratio; APTT-T: activated partial thromboplastin time; AAA: abdominal aortic aneurysm; PCR: platelet count recovery

Patient, aneurysm and treatment characteristics in groups with and without PCR

We then compared various characteristics between patients divided into a PCR(−) group (PCR <118%, N=126, 61% of the entire cohort with platelet count measures on POD7) and a PCR(+) group (PCR ≥118%). Table 1 shows demographic and preoperative factors, and Table 2 summarizes EVAR- and AAA-related parameters.

Sex and smoking history differed significantly between PCR(−) and PCR(+) groups. Preoperative platelet count was also slightly but significantly lower in the PCR(+) group compared with the PCR(−) group (p=0.01) (Table 1). Mean size and the prevalence of saccular-
shaped aneurysms did not differ between the groups. The EVAR treatment variables stent-graft model, details of the proximal neck and distal landing iliac arteries, and operating time also did not differ between the groups. Alternatively, more PCR(−) patients received red blood cell transfusions than PCR(+) patients (p = 0.001).

**Overall survival and cumulative aneurysm sac expansion rates**

Overall survival rates did not differ between PCR(+) and PCR(−) groups over 5 years post-EVAR (Fig. 3a). On the other hand, the cumulative aneurysm sac expansion rate (% of patients) was significantly higher in the PCR(−) than the PCR(+) group (34.4% vs. 12.8% at 5 years, p = 0.01) (Fig. 3b). Results of univariate and multivariate Cox proportional-hazard analyses of factors related to cumulative aneurysm sac expansion rate are summarized in Table 3 and in the Supplemental Table. Univariate analysis revealed age (>80 years), female sex, dual antiplatelet therapy (DAPT), lack of PCR (PCR(−) status), EL, and a short aortic neck (<10 mm) as risk factors of sac expansion. Multivariate analysis identified age, EL, and short aortic neck (<10 mm) as significant independent predictors.

**Discussion**

Several studies have documented reduced platelet counts in the days following EVAR.14,15 This response is also accompanied by changes in white blood cell count and C-reactive protein, which are well-known inflammation markers, suggesting that reduced platelet count is due to a postoperative inflammatory response (termed 'post-implantation syndrome'). Generally, platelet count decreases from roughly 190–200 × 10^3/µL before surgery to 150–160 × 10^3/µL on POD1 to POD3.13–15 This change is consistent with the 20%–30% decrease observed 24 and 72h post-EVAR in the current study. Platelet count then rose, frequently above presurgical baseline, on POD7. These results suggest that platelet count is chronically suppressed in AAA patients and reversed after EVAR delay.

This chronic reduction may stem directly from blood coagulation disorder, causing the aortic aneurysm, as disseminated intravascular coagulation (DIC) has occurred in 4% of AAA patients.16 The aneurysm-induced DIC is suggested to be caused by a hemostatic imbalance due to exposure of the denuded aortic endothelial surface and regulatory dysfunction following the permanent trigger-

---

**Table 2** Characteristics of AAAs and treatment in the patients with and without optimal platelet count recovery

| Variables                        | Total (n=205) | PCR(+) (n=79) | PCR(−) (n=126) | P-value |
|----------------------------------|---------------|---------------|----------------|---------|
| Abdominal aortic aneurysm        |               |               |                |         |
| Size (mm)                        | 5.1±0.5 (5.0–5.3) | 5.3±0.9 (5.1–5.4) | 5.1±0.7 (4.9–5.2) | 0.08    |
| Shape (saccular)                 | 19 (9)        | 7 (9)         | 12 (10)        | 1.00    |
| Stent graft model                |               |               |                |         |
| Zenith                           | 60 (29)       | 30 (38)       | 30 (24)        | 0.30    |
| Powerlink                        | 19 (9)        | 7 (9)         | 12 (10)        |         |
| Excluder                         | 56 (27)       | 19 (24)       | 37 (29)        |         |
| Endurant II                      | 66 (32)       | 22 (28)       | 44 (35)        |         |
| Aorfix                           | 4 (2)         | 1 (1)         | 3 (2)          |         |
| Proximal landing                 |               |               |                |         |
| Aortic neck length (mm)          | 26.6±0.8 (25.0–28.2) | 26.8±1.4 (24.1–29.6) | 26.0±1.1 (23.9–28.2) | 0.65    |
| Aortic neck diameter (mm)        | 21.5±0.2 (21.1–22.0) | 22.1±0.4 (21.3–22.8) | 21.2±0.3 (20.6–21.8) | 0.09    |
| Aortic neck angle (<60°)         | 177 (86)      | 68 (86)       | 109 (87)       | 0.83    |
| Distal landing                   |               |               |                |         |
| Bil. common iliac artery landing | 180 (88)      | 69 (87)       | 111 (88)       | 1.00    |
| External iliac artery landing    | 16 (8)        | 6 (8)         | 10 (8)         |         |
| Bil. external iliac artery landing | 2 (1)       | 1 (1)         | 1 (1)          |         |
| Others                           | 7 (3)         | 3 (3)         | 4 (3)          |         |
| Operation time (min)             | 163±4 (155–171) | 160±7 (145–174) | 167±6 (155–178) | 0.46    |
| Blood loss (cc)                  | 303±24 (255–351) | 262±43 (177–348) | 337±34 (270–405) | 0.17    |
| Blood transfusion                |               |               |                |         |
| Red blood cells                  | 31 (15)       | 4 (5)         | 27 (21)        | 0.001   |
| Platelets                        | 2 (1)         | 1 (1)         | 1 (1)          | 1.00    |
| Fresh frozen plasma              | 3 (1)         | 0 (0)         | 3 (2)          | 0.29    |

**Bil.:** bilateral. Other abbreviations defined in Table 1.
ing of coagulation factors. Therefore, a reduced platelet count is an important and relatively sensitive (although not specific) sign of DIC. In contrast to platelet count, Yamazumi et al. reported that hemostatic factors, such as thrombin–antithrombin III complex (TAT), D-dimer and fibrinogen/fibrin degradation products, were significantly higher in AAA patients than healthy controls. They also reported that the values of these hemostatic factors improved but were not completely normalized by EVAR. In contrast, only below-normal platelet counts were significantly increased among AAA patients three months after open repair. These findings collectively indicate that almost all AAA patients suffer more or less from chronic DIC or coagulopathy. Then, platelet count reduction due to AAA recovers soon after successful EVAR, curing the coagulation dysfunction with a complete sealing of the aneurysmal aortic wall. Furthermore, the postoperative inflammatory response contributing to platelet count reduction and the platelet activation indicated by biomarker expression (CD62P-CD36) were correlated with the volume of new-onset thrombus in AAA with AAA volume. Hence, platelet abundance and function rather than hemostatic factors appear to be more sensitive biomarkers for EVAR success and AAA prognosis.

In this study, PCR at POD7 was negatively influenced by EL, as patients showing persistent EL also exhibited significantly attenuated PCR. Further, a poor PCR was a risk factor for aneurysm sac expansion following EVAR in our univariate analysis (Table 3). Moreover, the multivariate analysis disclosed age, EL, and short aortic neck (<10 mm) as independent risk factors. These results are in line with previous studies, which identified age, anatomical condition of aortic neck, and antiplatelet therapy as risk factors for aneurysm sac expansion after EVAR. Aortic short neck is a risk factor of type

![Image](56x365 to 284x718)

**Table 3** Multivariate analysis of factors related to cumulative aneurysm sac expansion rate

| Variables                          | Univariate       | Multivariate   |
|------------------------------------|------------------|----------------|
|                                    | HR   | 95% CI | P value | HR   | 95% CI | P value |
| Characteristics and comorbidities  |      |        |         |      |        |         |
| Age (>80 years)                    | 3.00 | 1.36–6.55 | 0.007 | 2.82 | 1.21–6.59 | .0169 |
| Sex (female)                       | 3.67 | 1.61–8.00 | <0.01 | 2.10 | 0.85–4.99 | .1050 |
| Medication                         |      |        |         |      |        |         |
| Antiplatelet therapy               | 1.66 | 0.70–4.07 | 0.08  | 1.49 | 0.59–3.95 | .4030 |
| SAPT vs. none                      | 4.60 | 1.40–13.46 | 0.01  | 5.92 | 1.67–19.59 | .0076 |
| DAPT vs. none                      | 2.77 | 0.67–7.59 | 0.08  | 3.98 | 1.17–12.36 | .0290 |
| Laboratory data                    |      |        |         |      |        |         |
| Disturbed PCR                      | 3.68 | 1.39–12.66 | 0.007 | 3.68 | 1.28–13.50 | .0141 |
| Aneurysms and treatments           |      |        |         |      |        |         |
| Aortic neck length (<10 mm)        | 5.42 | 1.56–14.49 | 0.01  | 12.51 | 3.20–41.98 | .0009 |
| Endoleak                           | 107.36 | 14.52–794.09 | <0.0001 | 97.5 | 12.36–769.61 | <0.0001 |

HR: hazard ratio; CI: confidence interval. Other abbreviations are the same as in Table 1.
Ia endoleak, which brings massive blood flow to the aneurysm sac and can cause rapid sac expansion. In our analysis, EL, a suggested risk of aneurysm sac expansion, included type I and III ELs. Hence, these results might reflect that type I and III ELs were the most important risk factors of EVAR failure with aneurysm sac expansion. In the real world, however, most type I and III ELs are easily detected with the standard follow-up examinations using CT and/or ultrasound imaging. Therefore, the remaining issue is the prediction and early detection of delayed and late aneurysm sac expansion. This type of sac expansion was believed to be caused mainly by type II EL. On the other hand, “occult” type I or III EL is suggested to account for more than 20% of type II ELs with treatment failure and/or covert rapid aneurysm sac growth. In some difficult cases, an accurate diagnosis of the type of EL relies entirely on imaging with an enhanced medium such as enhanced CT and angiography. This fact is inconvenient for AAA patients because their renal function is known to decline during follow-up after EVAR. In this study, we revealed that disturbed PCR, which can be revealed by a simple blood test, is associated with type-II EL with aneurysm sac expansion as well as type I and III ELs (Fig. 2). This result implies that the serological approach and imaging-based examinations can be a useful and less invasive option to improve postprocedural surveillance accuracy after EVAR.

This study has several limitations. This was a retrospective single-center study with limited sample numbers, which may introduce selection bias and limit the statistical power for the identification of additional risk factors. Second, PCR was based on the CBC test, which is expensive, but only an indirect estimation of platelet count. Also, the platelet count can be affected by other systemic conditions, such as hypervolemia and hypovolemia, as well as by AAA. Finally, the retrospective study design precludes the investigation of causal relationships among PCR, EL, and aneurysm sac expansion. Further studies are required for the optimization of EVAR follow-up, such as using platelet activity-specific markers.

Conclusion

Platelet count shows the temporal ‘dip’ reduction during POD1–3 followed by recovery up to 112% on POD7 after EVAR. ELs can attenuate the PCR, and the disturbed PCR may be associated with aneurysm sac expansion after EVAR.

Disclosure Statement

All authors have no conflict of interest.

Author Contributions

Study conception: KI
Data collection: KI, SK, SYo, KN, SYa
Analysis: KI
Investigation: KI, TF, KM, MM
Writing: KI
Critical review and revision: all authors
Final approval of the article: all authors
Accountability for all aspects of the work: all authors

Supplementary Materials

Supplementary materials are available at the online article sites on J-STAGE and PMC.

References

1) Schanzer A, Greenberg RK, Hevelone N, et al. Predictors of abdominal aortic aneurysm sac enlargement after endovascular repair. Circulation 2011; 123: 2848-55.
2) O’Donnell TFX, Deery SE, Boitano LT, et al. Aneurysm sac failure to regress after endovascular aneurysm repair is associated with lower long-term survival. J Vasc Surg 2019; 69: 414-22.
3) Deery SE, Ergul EA, Schermerhorn ML, et al. Aneurysm sac expansion is independently associated with late mortality in patients treated with endovascular aneurysm repair. J Vasc Surg 2018; 67: 157-64.
4) Guo Q, Du X, Zhao J, et al. Prevalence and risk factors of type II endoleaks after endovascular aneurysm repair: a meta-analysis. PLoS One 2017; 12: e0170600.
5) Álvarez Marcos F, Llaneza Coto JM, Franco Mejide FJ, et al. Effect of antiplatelet therapy on aneurysmal sac expansion associated with type II endoleaks after endovascular aneurysm repair. J Vasc Surg 2017; 66: 396-403.
6) van Marrewijk CJ, Fransen G, Laheij RJ, et al. Is a type II endoleak after EVAR a harbinger of risk? causes and outcome of open conversion and aneurysm rupture during follow-up. Eur J Vasc Endovasc Surg 2004; 27: 128-37.
7) Lal BK, Zhou W, Li Z, et al. Predictors and outcomes of endoleaks in the Veterans Affairs Open Versus Endovascular Repair (OVER) Trial of abdominal aortic aneurysms. J Vasc Surg 2015; 62: 1394-404.
8) El Batt S, Cochennece F, Roudot-Thoraval F, et al. Type II endoleaks after endovascular repair of abdominal aortic aneurysm are not always a benign condition. J Vasc Surg 2013; 57: 1291-7.
9) Wanhainen A, Verzini F, Van Herzeel I, et al. Editor’s choice—European Society for Vascular Surgery (ESVS) 2019 clinical practice guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg 2019; 57: 8-93.
10) Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg 2018; 67: 2-77.e2.
11) Lin PH, Bush RL, Katzman JB, et al. Delayed aortic aneu-
Abdominal aortic aneurysm enlargement due to endotension after endovascular repair. J Vasc Surg 2003; 38: 840-2.

12) van Sambeek MR, Hendriks JM, Tseng L, et al. Sac enlargement without endoleak: when and how to convert and technical considerations. Semin Vasc Surg 2004; 17: 284-7.

13) Arnaoutoglou E, Kouvelos G, Papa N, et al. Platelet activation after endovascular repair of abdominal aortic aneurysm. Vascular 2016; 24: 287-94.

14) Arnaoutoglou E, Kouvelos G, Papa N, et al. Prospective evaluation of postimplantation syndrome evolution on patient outcomes after endovascular aneurysm repair for abdominal aortic aneurysm. J Vasc Surg 2016; 63: 1248-55.

15) Kakisis JD, Moulakakis KG, Antonopoulos CN, et al. Volume of new-onset thrombus is associated with the development of postimplantation syndrome after endovascular aneurysm repair. J Vasc Surg 2014; 60: 1140-5.

16) Fisher DF Jr, Yawn DH, Crawford ES. Preoperative disseminated intravascular coagulation associated with aortic aneurysms. A prospective study of 76 cases. Arch Surg 1983; 118: 1252-5.

17) Fernandez-Bustamante A, Jimeno A. Disseminated intravascular coagulopathy in aortic aneurysms. Eur J Intern Med 2005; 16: 551-60.

18) Takemitsu T, Wada H, Hatada T, et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost 2011; 105: 40-4.

19) Wada H, Gabazza EC, Asakura H, et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol 2003; 74: 17-22.

20) Yamazumi K, Ojiri M, Okumura H, et al. An activated state of blood coagulation and fibrinolysis in patients with abdominal aortic aneurysm. Am J Surg 1998; 175: 297-301.

21) Png CYM, Tadros RO, Beckerman WE, et al. An anatomic risk model to screen post endovascular aneurysm repair patients for aneurysm sac enlargement. J Surg Res 2017; 217: 29-35.e1.

22) AbuRahma AF, Mousa AY, Campbell JE, et al. The relationship of preoperative thrombus load and location to the development of type II endoleak and sac regression. J Vasc Surg 2011; 53: 1534-41.

23) Goudeketting SR, van Noort K, Ouriel K, et al. Influence of aortic neck characteristics on successful aortic wall penetration of EndoAnchors in therapeutic use during endovascular aneurysm repair. J Vasc Surg 2018; 68: 1007-16.

24) Madigan MC, Singh MJ, Chaer RA, et al. Occult type I or III endoleaks are a common cause of failure of type II endoleak treatment after endovascular aortic repair. J Vasc Surg 2019; 69: 432-9.

25) Funaki B, Birouti N, Zagan SM, et al. Evaluation and treatment of suspected type II endoleaks in patients with enlarging abdominal aortic aneurysms. J Vasc Interv Radiol 2012; 23: 866-72; quiz, 872.

26) Saratzis A, Bath MF, Harrison S, et al. Long-term renal function after endovascular aneurysm repair. Clin J Am Soc Nephrol 2013; 10: 1930-6.